Evaluating ITI-007 in patients with behavioral disturbances associated with dementia, including Alzheimer's disease.

Trial Profile

Evaluating ITI-007 in patients with behavioral disturbances associated with dementia, including Alzheimer's disease.

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Therapeutic Use
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 28 Apr 2016 According to Intra-Cellular Therapies media release, the company plans to initiate this trial in the second quarter of 2016.
    • 05 Nov 2015 According to an Intra-Cellular Therapies media release, the company plans to initiate this Phase II trial in the first half of 2016.
    • 15 Jun 2015 According to an Intra-Cellular Therapies media release, the company plans to initiate this Phase II trial in later in 2015, hence the planned initiation date changed from 1 Jan 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top